GlassScriptPhysician profile
Amir Shbeeb
NPI 1700143617
$216,418.04
in general payments reported to CMS, 2019-2025
13 companies · $5,204 in 2025
The $5,204 reported for 2025 was more than what 98% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,213 · 2020: $5,815 · 2021: $72K · 2022: $74K · 2023: $49K · 2024: $6,447 · 2025: $5,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $21K · Food and Beverage: $2,515 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,640.00 |
| Travel and Lodging | $20,852.32 |
| Food and Beverage | $2,515.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $191,389.58 | 2020-2025 | Exparel, Iovera, Zilretta |
| Edwards Lifesciences Corporation | $10,675.00 | 2019-2024 | Hemosphere |
| Baxter Healthcare | $6,795.00 | 2019-2022 | |
| Becton, Dickinson and Company | $4,300.00 | 2025 | Hemosphere |
| Verathon INC. | $1,375.00 | 2020 | |
| Zimmer Biomet Holdings, INC. | $482.21 | 2020-2025 | Persona, Oss Orthopedic Salvage System, Osseoti Reconstructive System |
| Fisher & Paykel Healthcare INC | $377.36 | 2023-2024 | Fisher & Paykel Healthcare |
| Vertex Pharmaceuticals Incorporated | $376.74 | 2025 | |
| Heron Therapeutics, INC. | $200.87 | 2022-2025 | Aponvie, Zynrelef |
| Chiesi USA, INC. | $144.26 | 2021 | |
| Vyaire Medical, INC. | $119.74 | 2022 | |
| Merck Sharp & Dohme LLC | $112.84 | 2019 | |
| Biotronik INC. | $69.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Shbeeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.